阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察

发布时间：2018-02-24 16:11

本文关键词： 乳腺肿瘤分子靶向治疗阿帕替尼转移　出处：《中国肿瘤临床》2017年15期 　论文类型：期刊论文

【摘要】：目的:评价阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效及不良反应。方法:回顾性分析2015年7月至2016年11月就诊于天津医科大学肿瘤医院,经病理学确诊为晚期三阴性乳腺癌,既往接受过两线以上化疗后疾病进展(progressive disease,PD)、服用阿帕替尼500 mg/d治疗的8例患者临床资料,所有患者均在接受2个周期以上治疗后评价疗效,观察PD时间、有效率、临床获益率及不良反应。结果:8例患者共接受平均4个周期的治疗,经过中位随访时间为8(4~11)个月,其中部分缓解(partial remission,PR)4例,疾病稳定(stable disease,SD)3例,PD 1例;疾病控制率(disease control rate,DCR)为87.5%(7/8),客观缓解率(objective response rate,ORR)为50%(4/8),平均无进展生存期(progression free survival,PFS)为4.2个月。不良反应为手足综合征(3/8)、骨髓抑制(4/8)、高血压(2/8)、蛋白尿(3/8)、咯血(1/8)、恶心(2/8)、乏力(2/8)等。结论:阿帕替尼在三阴性乳腺癌的治疗中可获得一定的疗效及生存获益,且安全性好,不良反应可控。
[Abstract]:Objective: to evaluate the clinical efficacy and adverse reactions of apatinib in the treatment of advanced refractory triple negative breast cancer. Methods: from July 2015 to November 2016, Apatinib was admitted to Tianjin Medical University Oncology Hospital. The clinical data of 8 patients with advanced three-negative breast cancer diagnosed by pathology, who had been treated with more than two doses of chemotherapy and progressive disease, and who were treated with apatinib 500 mg/d, were all evaluated after two cycles of treatment. Results eight patients received an average of 4 cycles of treatment, with a median follow-up time of 8 ~ 411 months, including 4 cases with partial partial remissioning PRA and 1 case with PD with stable disease SDN. The disease control rate is 87.5%, the objective remission rate is 50% / 8%, the average progression-free survival time is 4.2 months. The adverse reactions are hand and foot syndrome 3 / 8, bone marrow depression 48%, hypertension 2% -8%, proteinuria 3% -8%, hemoptysis 1.8%, nausea 2% -8%, fatigue 2% -8%. Conclusion: Apatinib can obtain certain curative effect and survival benefit in the treatment of triple negative breast cancer. And the safety is good, the adverse reaction is controllable.
【作者单位】：天津医科大学肿瘤医院乳腺肿瘤内科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心乳腺癌防治教育部重点实验室;
【基金】：国家科技支撑计划课题项目(编号:2015BAI12B15) 卫生局攻关项目(编号:16KG128)资助~~
【分类号】：R737.9

【相似文献】